Scientist target glucagon pathway for treating type 2 diabetes

04/12/2012 | HealthDay News

Inhibiting the CaMKII enzyme glucagon pathway helped lower blood glucose and cholesterol levels, prevent fatty liver deposits and boost insulin sensitivity without adverse effects in obese mice with type 2 diabetes, a study in Cell Metabolism showed. "When you eat a meal and your sugar goes up, glucagon and glucose should switch off, but that doesn't happen in type 2 diabetes," said Dr. Vivian Fonseca, president for medicine and science at the American Diabetes Association.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN